News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:
   

Bertin Pharma And Indigo Biosciences, Inc. Sign Agreement For Distributing Nuclear Receptor Assay Kits In Europe



11/15/2016 10:21:37 AM

MONTIGNY-LE-BRETONNEUX, France--(BUSINESS WIRE)--Over 40 product references to assay nuclear receptors are now available for European researchers during their work in drug discovery and toxicology. These innovative tools are used for profiling compounds in research areas such as metabolic disorders, cardiovascular disease, or even endocrinology.

“It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.”

Innovative products to reduce time, cost and risk in drug discovery process

INDIGO Biosciences, leader in Nuclear Receptor Research, provides the world’s largest portfolio of Nuclear Receptor Assay kits using luciferase reporter technology. Those kits are all-inclusive, cell-based, robust, and ready to use for either screening small numbers of test compounds or HTS application.

Expansion to Europe

With a fast-growing business in the USA, INDIGO Biosciences wishes to benefit from increased European exposure to capture new market shares.

Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to the research and development for the pharmaceutical, cosmetic and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its International distributor channels enable to deliver life science tools on time and to support customers throughout their experimentation.

Bertin Pharma completes, with this new range of Nuclear Receptor Assay kits, its existing ranges of biomarker assays applied to his expertise areas that are metabolic syndrome, hypertension or even oncology.

It has been a real honor to be introduced to Fred and his company and we rapidly found a lot of complementarity in our business. The Nuclear Assay range perfectly fit with our customer’s needs, and will empower our commercial activity.” Said Patrick Vitaux, Bioreagent Dpt Manager – Bertin Pharma

“We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO’s assay portfolio to their customers throughout the region.” Fred Marroni, CEO – INDIGO Biosciences

> Watch video

> Discover our products

About INDIGO Biosciences

Learn more about INDIGO Bioscience

About Bertin Pharma

Learn more about Bertin Pharma

INDIGO Biosciences
Fred Marroni (814)234-1919
or
Bertin Pharma
Frédérique Vigezzi - Gootenberg, +33 (0)143 59 2984


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES